Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lawmakers seek scientific review of plan to tightly regulate all fentanyl copycats

Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.

Read More »

Nektar Forms New Subsidiary

With an opioid molecule awaiting regulatory review, Nektar Therapeutics announced the launch of Inheris Biopharma, which will be responsible for the commercialization of NKTR-181.

Read More »

Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain

Heron Therapeutics Inc. announced that the company received a Complete Response Letter from the U.S. Food and Drug Administration on April 30, 2019 regarding the New Drug Application for HTX-011 for the management of postoperative pain.

Read More »

White Paper: Safety Profile of the Analgesic Trezix™ Capsules, Containing the Mild Opioid Dihydrocodeine

Privately held pharmaceutical company Wraser Pharmaceuticals announced the publication of a White Paper addressing opioid safety.

Read More »

Pfizer-Lilly drug shown to help reduce back pain in late-stage trial

A non-opioid painkiller developed by Pfizer Inc. and Eli Lilly and Co. succeeded in reducing chronic low back pain when used in a stronger dose, results from a late-stage study showed.

Read More »

Glenmark Adds 400 Employees, Spins off Innovation Business

Mumbai-based Glenmark Pharmaceuticals is spinning off its innovation business into a U.S.-based standalone company.

Read More »

New Test Measures Pain Levels Using Biomarkers in the Blood

As the United States continues to grapple with the opioid epidemic, researchers have developed a new test that can measure pain biomarkers in the blood.

Read More »

Pfizer and Lilly’s New Type of Pain Drug Meets Endpoints in Osteoarthritis Phase III Trial

Pfizer and Eli Lilly announced that tanezumab hit two out of three co-primary endpoints in one dose and all three with a higher dose in patients with moderate-to-severe osteoarthritis pain in a Phase III trial.

Read More »

Pfizer forecasts 2019 revenue below Wall Street targets

Pfizer Inc. forecast 2019 profit and sales below Wall Street estimates as the company expects to take a blow from a stronger dollar and as well as the loss of patent on the blockbuster pain treatment Lyrica during 2019.

Read More »

Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations

Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom